Objective: To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons.
T HE PRESENCE OF LYMPH NODE
metastasis has important implications in the prognosis and treatment of patients with colorectal cancer. 1 Observational studies indicate that the number of lymph nodes assessed by pathological examination (in particular, the negative node count) is associated with longer survival in colorectal cancer. 2 Thus, along with disease stage and tumor molecular features, the node count is often used for treatment decision making by oncologists. However, the optimal number of lymph nodes that must be assessed remains controversial. [2] [3] [4] [5] Although the average number of lymph nodes evaluated for colorectal cancer has increased in the past decade, it remains uncertain how the node count is influenced by demographic, clinical, and tumor molecular factors. 6, 7 The number of recovered lymph nodes may be influenced not only by surgeons and pathologists but also by factors independent of surgeons and pathologists. Those "operator-independent" factors include tumor location, disease stage, tumor size, host immune response, 8 and tumor molecular features, such as microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). 9 Molecular features of colorectal cancer and host immune re-sponse have been associated with the node count. 9, 10 Previous studies have examined the relationship between the recovered node count and various demographic and clinical features in population-based [11] [12] [13] [14] [15] [16] and hospital-based [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] studies, but all those studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 28, 29 lacked comprehensive data on specimen length, tumor size, host immune reaction to tumor, and tumor molecular features. Beyond surgeon-and pathologist-related (ie, operator) factors, it is important to identify patient-specific node count predictors (ie, clinical, pathological, or tumor molecular factors) to assess the adequacy of lymph node examination for each patient. To accomplish this aim, a comprehensive database of a large number of colorectal cancer cases with clinical, specimen, pathological, and molecular annotations is needed. We therefore conducted this molecular pathological epidemiology 8, 30 ,31 study using a database of 918 colorectal cancer cases in 2 prospective cohort studies. Considering the overall distribution of the node count, we used negative binomial regression analysis to identify factors associated with the negative and total node counts. Because we used a US nationwide cohort database with clinical, specimen, pathological, and tumor molecular variables (including MSI, CIMP, and KRAS (HGNC 6407), BRAF (HGNC 1097), and PIK3CA (HGNC 8975) mutations), we could assess each node count predictor independent of operator (surgeon and pathologist) factors.
METHODS

STUDY POPULATION
We used the databases of 2 prospective cohort studies: the Nurses' Health Study (consisting of 121 701 women who have been followed up since 1976) and the Health Professionals Follow-up Study (consisting of 51 529 men who have been followed up since 1986). 32, 33 Every 2 years, participants have been sent follow-up questionnaires to update information on potential risk factors and to identify newly diagnosed cancer in themselves and their first-degree relatives. For nonresponders, we searched the National Death Index to discover deaths and to ascertain the causes of death and any diagnosis of cancer. Study physicians reviewed medical records, including pathology reports, and recorded tumor location and pathological TNM (tumor-node-metastasis) stage, the positive and negative node counts, 9 tumor size, circumferential growth along the bowel wall, and resected colorectal length (specimen length). We collected paraffin-embedded tissue blocks from hospitals where patients underwent tumor resections. 33 We collected diagnostic biopsy specimens for patients with rectal cancer who received preoperative treatment to avoid artifacts or bias introduced by treatment. Based on the availability of data on the node count and tumor molecular features, we included a total of 918 colorectal cancer cases diagnosed up to 2006. Hospitals where our participants underwent colorectal resections were distributed throughout the United States (Figure 1) . Informed consent was obtained from all study subjects. This study was approved by the Human Subjects Committees at Brigham and Women's Hospital and the Harvard School of Public Health.
HISTOPATHOLOGICAL EVALUATIONS
Tissue blocks from all colorectal cancer cases were evaluated by a pathologist (S.O.). Tumor differentiation was categorized as poor vs well-moderate (Յ50% vs Ͼ50% glandular areas). The presence and extent of mucinous and/or a signet ring cell component were recorded. Lymphocytic reaction patterns, such as peritumoral lymphocytic reaction and tumor infiltrating lymphocytes, were examined as previously described. 34 A subset of cases (nϾ100) was reviewed by another pathologist (T.M.), and concordance was as follows: =0.72 for tumor differentiation, Spearman r=0.87 for the percentage of mucin, Spearman r=0.65 for the percentage of signet ring cells, and Spearman r=0.65 for the summation score of peritumoral reaction and tumor infiltrating lymphocytes.
PYROSEQUENCING OF KRAS, BRAF, AND PIK3CA
AND MSI ANALYSIS
We extracted DNA from each tumor, and polymerase chain reaction (PCR) analysis and pyrosequencing targeted for KRAS (codons 12 and 13), 35 BRAF (codon 600), 36 and PIK3CA (exons 9 and 20) 37 were performed. The MSI status was determined using D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487. 38, 39 We defined MSI-high as the presence of instability in 30% or more of the markers and microsatellite stability/MSI-low as instability in 0% to 29% of the markers.
ANALYSES OF 2 TYPES OF METHYLATION
Sodium bisulfite treatment on DNA and real-time PCR (MethyLight) assays were validated and performed. 40 38, 41, 42 We defined CIMP-high as 6 or more methylated markers and CIMP-low/0 as 0 to 5 methylated markers according to the previously established criteria. 38 To accurately quantify relatively high long interspersed nucleotide element 1 (LINE-1) methylation levels, we used pyrosequencing. 43, 44 
STATISTICAL ANALYSIS
We used SAS software (version 9. Figure 1 . Number of cases analyzed in this study by state. Our patients were distributed throughout the United States, and our results would not have been influenced by any particular surgeon or pathologist, thus increasing the generalizability of our findings.
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). The 2 test was used to assess the association between categorical variables, and analysis of variance was used to compare continuous variables across categories. We adopted multivariate negative binomial regression analysis to assess predictors of the node count because the marginal distribution of the total or negative node count fit the gammaPoisson-like distribution ( Figure 2) ; overdispersion occurred with Poisson generalized linear models. The process of estimation was based on a negative binomial distribution that can be conceptualized as a mixture of a Poisson distribution and a gamma distribution. 45 Variables initially included in a model were sex, age (continuous), prediagnosis body mass index (continuous), family history of colorectal cancer in any firstdegree relative, year of diagnosis (continuous), hospital setting (academic vs nonacademic), tumor size (continuous), specimen length (continuous), circumferential growth (100% complete vs incomplete), tumor location and TNM stage (categorized as in Table 1 and Table 2 ), tumor differentiation (poor vs well-moderate), mucinous component (reported as a continuous percentage), signet ring cells (reported as a continuous percentage), peritumoral lymphocytic reaction and tumor infiltrating lymphocytes (absent/minimal vs mild vs moderate vs marked; ordinal), MSI (MSI-high vs microsatellite stability/MSI-low), CIMP (CIMP-high vs CIMP-low/0), LINE-1 methylation (continuous), and KRAS, BRAF, and PIK3CA (mutations vs wild-type variants). A backward elimination with a threshold of P=.1 was performed to select variables in the final model except for TNM stage and tumor location, for which all categories were forced into the model. For cases with missing data in a covariate, we carried out 2 separate analyses: the first analysis included all patients, with creation of a categorical indicator for missing responses (missing indicator method; the second analysis included all patients, with missing responses imputed (multiple imputation [MI] ). The MI procedure in SAS was used to perform 20 imputations of all variables with missing cases by using the regression method. The results from the regression analysis were then appropriately combined by using the MIANALYZE procedure.
RESULTS
LYMPH NODE COUNT IN COLORECTAL CANCER RESECTION
The total node count showed a skewed (gamma-Poissonlike) distribution ( Figure 2 ): range, 0 to 54; mean, 12.0; median, 10; and interquartile range, 6 to 16 nodes. The negative node count also showed a skewed (gammaPoisson-like) distribution: range, 0 to 54; mean, 10.5; median, 8; and interquartile range, 4 to 15 nodes. Tables 1 and 2 show the clinical, pathological, and molecular features of colorectal cancers according to quartiles of the negative or total node count. The negative and total node counts were both positively associated with specimen length, tumor size, ascending colon location, T3N0M0 stage, MSI status, and CIMP status (all PϽ.001).
NODE COUNT AND CLINICAL, PATHOLOGICAL, AND MOLECULAR FEATURES
MULTIVARIATE ANALYSIS FOR THE NODE COUNT
In a multivariate negative binomial regression model, factors independently associated with the negative node count included specimen length, tumor location, TNM stage, year of diagnosis, and tumor size (all P Յ .002) ( Table 3 ). In Table 3 , for example, specimens with rectal cancer on average yielded a negative node count of approximately two-thirds (0.67) of that in specimens with ascending colon cancer after controlling for the effects of other variables. A KRAS mutation appeared to be a predictor of the negative node count (P=.03), although multiple hypothesis testing should be considered and the finding confirmed by an independent data set. Factorsindependentlyassociatedwiththetotalnodecount included specimen length, tumor location, TNM stage, and tumor size after controlling for the effects of other variables (all PϽ.001) ( Table 4) . A KRAS mutation appeared to be a predictor of the total node count (P=.009), although multiple hypothesis testing should be considered.
NODE COUNT IN NODE-NEGATIVE (STAGES I AND II) COLORECTAL CANCER RESECTIONS
In patients with stage I or II colorectal cancer, ascending colon tumor location, tumor size, and specimen length were positively associated with the node count after controlling for the effects of other variables (all PՅ.002) ( Table 5) . Mutations of PIK3CA (P=.03) and KRAS (P=.049) also ap- peared to predict the node count, although multiple hypothesis testing should be considered.
COMMENT
We conducted this study to identify clinical, pathological, and tumor molecular variables that predict the node count in colorectal cancer resections independent of human operator factors (ie, surgeons and pathologists). We found that specimen length, tumor size, T3N0M0 stage, ascending colon tumor location, and year of diagnosis were positively associated with the negative node count.
Mutation of KRAS might also be positively associated with the negative node count, but this finding should be confirmed by an independent data set. These results indicate that operator-independent variables influence the node count in colorectal resection and should be examined in any future study that assesses the adequacy of lymph node harvesting and staging.
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a Unless otherwise indicated, data are given as number (percentage) indicating the proportion of cases with a specific clinical, pathological, or molecular feature among a given quartile category of the negative or total node count. Denominators vary because of missing data.
b P values were calculated by analysis of variance for age, tumor size, and long interspersed nucleotide element 1 methylation and by 2 test for all other variables. Because of multiple hypothesis testing, a P value for significance was adjusted by Bonferroni correction to .0023. larger tumor size, 11, 14, 18, 20 the number of vascular pedicles, 50 and higher disease stage. 17, 18 However, those studies 11, 13, 14, [17] [18] [19] [20] [21] [22] [23] [24] 28 produced no data on host immune response to tumor or tumor molecular features despite the possible influence of immune reaction and tumor molecular variables on the node count. 9 Previous studies that examined the relationship between MSI and the node count lacked specimen length and molecular variables besides MSI. 51, 52 In contrast to all previous studies that examined potential predictors of the node (15) 19 (9) 13 (6) 11 (5) Ͻ.001
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b P values were calculated by analysis of variance for age, tumor size, and LINE-1 methylation and by 2 test for all other variables. Because of multiple hypothesis testing, a P value for significance was adjusted by Bonferroni correction to .0023. count, 11, 13, 14, [17] [18] [19] [20] [21] [22] [23] [24] 28 we have used a US nationwide cohort database with well-annotated clinical, specimen, pathological, and tumor molecular data, including MSI, CIMP, and KRAS, BRAF, and PIK3CA mutations, all of which are potential predictors of the node count.
With regard to the influence of medical care quality or socioeconomic status on the lymph node count, 12, 53 academic hospital status 5, 14, 25 and the degree of practicing experience of the surgeons 11, 18 and pathologists 11, 13, 17, 18, 54 have been associated with the node count (for review, see Storli et al 55 ). However, all but three 14, 18, 24 of those previous studies on medical care quality or socioeconomic status 5, 11, 13, 16, 17, 53, 54 lacked data on specimen length.
Our ability to use the database of 2 US nationwide prospective cohort studies to assess operator-independent predictors of the node count provided advantages. First, cohort participants who developed cancer were treated at hospitals throughout the United States (Figure 1 ) and were more representative of colorectal cancer cases in the general US population than one might expect of patients in 1 to a few hospitals. Second, because of our study design, any particular surgeon or pathologist could not have influenced our results, increasing the generalizability of our findings. Third, our rich molecular pathological epidemiology 8, 30, 31 database enabled us to simultaneously assess a number of variables and to adjust for potential confounding.
One weakness of our study is that participants of our cohort studies were US health professionals and predominantly non-Hispanic white individuals, thus constituting a rather homogeneous group, and the studies lacked other occupational and ethnic groups. One of the primary reasons for selecting health professionals as subjects in the cohort studies was that they have a good understanding of various diseases as well as of the value of the cohort studies, which increases the reliability and completeness of questionnaire-based follow-up and data collection. Second, we excluded a subset of cancer cases without available tumor tissue, which might cause bias. Nonetheless, the tumor specimen procurement rate has been 60% to 70% of attempts, and a previous study has shown that there is no substantial demographic or clinical difference between cases with and without tumor tissue analyzed. 32 Our ultimate goal is to determine how many nodes must be harvested to attain optimal care when devising an individualized treatment plan in each case. To achieve this goal, we need to assemble an adequate database with prospective follow-up to record detailed outcome data, preferably in a trial setting. We do not have enough data now to recommend a specific number of nodes that should be examined for optimal patient care. Nonetheless, our unique data set, which has provided strong evidence of the effects of specimen length, tumor size, tumor location, and TNM stage on the node count, will likely serve as a guide for future trials. a Variables (potential predictors) initially included in a regression model were the variables listed in the table, sex, age, body mass index, family history of colorectal cancer, year of diagnosis, hospital setting, circumferential growth, tumor differentiation, mucinous component, signet ring cells, peritumoral lymphocytic reaction, tumor infiltrating lymphocytes, CpG island methylator phenotype, microsatellite instability, long interspersed nucleotide element 1 methylation, and BRAF mutation. A backward elimination with a threshold of P = .1 was used to select variables in the final model. The adjusted fold change in mean node count by a given variable represents the exponential of the adjusted ␤ coefficient derived by the final model. Because of multiple hypothesis testing, a P value for significance was adjusted by Bonferroni correction to .0023. a Variables (potential predictors) initially included in a regression model were the variables listed in the table, sex, body mass index, family history of colorectal cancer, hospital setting, tumor differentiation, mucinous component, signet ring cells, tumor infiltrating lymphocytes, CpG island methylator phenotype, microsatellite instability, long interspersed nucleotide element 1 methylation, and BRAF and PIK3CA mutations. A backward elimination with a threshold of P = .1 was used to select variables in the final model. The adjusted fold change in mean node count by a given variable represents the exponential of the adjusted ␤ coefficient derived by the final model. Because of multiple hypothesis testing, a P value for significance was adjusted by Bonferroni correction to .0023.
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In conclusion, our study has shown that specimen length, tumor size and location, and TNM stage are predictors of the lymph node count in colorectal cancer resections independent of operator (surgeon and pathologist) factors. In addition, some tumor molecular features, such as KRAS mutation, might influence the node count but must be confirmed by an independent data set. Our data suggest that these clinical, pathological, specimen, and molecular variables should be examined as crucial elements in any future evaluation of the adequacy of lymph node examination for patients with colorectal cancer.
